Evidence map›Paper›PMID 39625298›Full record

ArticleEuropean journal of neurology2025

Levodopa-entacapone-carbidopa intestinal gel: Data from the Swedish national registry for Parkinson's disease.

Mezin Öthman, Filip Bergquist, Per Odin, Monica Scharfenort, Anders Johansson, Ioanna Markaki, Per Svenningsson, Nil Dizdar, Dag Nyholm

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Mezin ÖthmanDepartment of Medical Sciences, Neurology, Uppsala University, Uppsala, Sweden.ORCID 0009-0007-7139-8561
Filip BergquistDepartment of Pharmacology, University of Gothenburg, Gothenburg, Sweden.ORCID 0000-0002-3437-0267
Per OdinDivision of Neurology, Department of Clinical Sciences Lund, Faculty of Medicine, Lund University, Lund, Sweden.ORCID 0000-0002-0756-7478
Monica ScharfenortDivision of Neurology, Department of Clinical Sciences Lund, Faculty of Medicine, Lund University, Lund, Sweden.ORCID 0000-0003-4415-1428
Anders JohanssonSection of Neurology, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0002-3928-5184
Ioanna MarkakiSection of Neurology, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0003-3328-5746
Per SvenningssonSection of Neurology, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0001-6727-3802
Nil DizdarDepartment of Neurology and Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.ORCID 0000-0002-9556-6984
Dag NyholmDepartment of Medical Sciences, Neurology, Uppsala University, Uppsala, Sweden.ORCID 0000-0001-9776-7715

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLevodopa-entacapone-carbidopa intestinal gel (LECIG) was introduced on the Swedish market in 2019. The therapy is aimed at patients with Parkinson's disease (PD) with fluctuations and dyskinesias. Long-term efficacy and safety data are lacking.

objectiveTo investigate the efficacy, tolerability, and safety of LECIG in regular clinical practice for Parkinson's disease in Sweden.

methodsReal-world data were collected from the Swedish registry for Parkinson's disease (ParkReg) for all patients reported to receive LECIG during the period from 2019 until 31 August 2022.

resultsA total of 150 patients were identified. Sixty-one (41%) of 150 patients were females. At the start of treatment, the median age was 73 years (range: 43-86). The median duration since motor symptoms onset was 17 years (IQR: 9). Fifty (33%) of 150 patients switched from another device-assisted therapy, mostly LCIG (39 patients). Reported complications were mainly related to PEG-J tube and stoma (30%). Twenty (13.3%) of 150 patients discontinued LECIG and 11 (7.3%) patients died while on LECIG. The Parkinson KinetiGraph scores for bradykinesia, dyskinesia, fluctuations, tremor, and immobility for 53 patients during LECIG showed good therapy control. The median (IQR) p-Hcy during LECIG was 12 (4.6) μmol/L (n = 44). The median (IQR) PDQ-8 summary index during LECIG was 31 (17) (n = 52). The median (IQR) EQ5D during LECIG was 0.62 (0.32) (n = 41).

conclusionsData from ParkReg covering 150 patients over 3 years show LECIG to be an effective and safe device-aided therapy for advanced PD. However, the long-term efficacy and tolerability of LECIG need to be further investigated.

Indexed as

Antiparkinson AgentsCarbidopaCatecholsDrug CombinationsGelsLevodopaParkinson DiseaseRegistriesAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedNitrilesAntiparkinson AgentsCarbidopacarbidopa, levodopa drug combinationCatecholsDrug CombinationsentacaponeGelsLevodopaNitrileslevodopaParkinson's diseaseregistriesSweden

Identifiers

PMID39625298
PMCPMC11613213

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.